GlaxoSmithKline announced its acquisition of Nuvalent for $10.6 billion in cash, marking the British pharmaceutical giant's largest deal in eight years. The move represents a significant strategic pivot, as GSK is re-entering the oncology space after previously winding down its cancer portfolio. The all-cash transaction values Nuvalent's shares at $209 per share, and GSK expects the deal to close in 2024, subject to regulatory approvals and customary closing conditions.

The acquisition raises important questions about GSK's capital allocation strategy and its commitment to rebuilding presence in oncology, a therapeutically competitive but commercially important sector. Key factors to monitor include whether the deal closes at the announced terms, how GSK integrates Nuvalent's pipeline and operations into its existing structure, and whether this signals additional oncology-focused acquisitions or partnerships as the company reshapes its portfolio.